Banca de DEFESA: Ronaldo Coelho Silva

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : Ronaldo Coelho Silva
DATE: 27/08/2024
TIME: 14:00
LOCAL: Plataforma Virtual Microsoft Teams
TITLE:

New neuroprotective drugs for Parkinson’s disease: peptides isolated from the venom of free wasps and associated with nanoformulations

 

KEY WORDS:

Parkinson’s disease; Neurovespina; nanotechnology; 6-OHDA; neurodegeneration

PAGES: 100
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

Parkinson's disease (PD) is a neurodegenerative pathology with enormous social and psychological losses in the lives of those affected. The causes of the onset of the disease still remain unclear, as the disease has multifactorial components. The main pathophysiological characteristics of the disease are the degeneration of dopaminergic neurons in the Basal Nuclei, especially the Substantia Nigra (SN) and the presence of eosinophilic inclusion bodies in the cytoplasm of neurons, known as Lewy bodies. The absence of approved medicines in humans capable of altering the evolution of the disease, in addition to the adverse effects associated with existing conventional treatments, results in an urgency in the development of new strategies to study the disease and more effective treatments that make it possible to modify the course of the pathology. The present work aimed to evaluate the neuroprotective activity of the synthetic peptide Neurovespina (an analogue of the peptide isolated from social wasps) in its free form and associated with nanotechnology, in the murine model of Parkinson's Disease by unilateral intrastriatal injection of the neurotoxin 6-OHDA. 3 test days were used to evaluate, two administrations per day of the free peptide (or one per day associated with nanotechnology) for 7 days, the effects of the free peptide and associated with nanotechnology. The assessment of motor impairment was measured using the RotaRod equipment using fall latency, showing a statistical difference between the Sham and Injury Control (6-OHDA) groups. The cylinder test was performed to evaluate the asymmetry of the forelimbs during the exploration task and showed no statistically significant difference between the groups. The neuron count revealed a statistically significant difference (between the injured side and the healthy side) in the nanoneuro and injury control groups. In the analysis of remaining THr neurons (percentage in relation to the contralateral side) in the SN, only the Neurovespina group did not show a statistically significant difference when compared with the Sham group. Inspection of striatal Optical Density demonstrated a statistically significant difference (between healthy and injured sides) in all treatment groups with the exception of the Sham group. The results of this work indicate and corroborate the neuroprotective action of the synthetic peptide Neurovespin (in its free form) on SN dopaminergic neurons, after intrastriatal 6-OHDA injury, as a potential model drug for the development of new neuroactive molecules for the study of DP.

COMMITTEE MEMBERS:
Externa à Instituição - CRISTINA APARECIDA JARK STERN - UFPR
Externo à Instituição - SERGIO HENRIQUE DE SOUZA ALVES - UNICEUB
Interna - 2937927 - DJANE BRAZ DUARTE
Presidente - 1952915 - RAFAEL PLAKOUDI SOUTO MAIOR
Externo ao Programa - 1161674 - VITOR AUGUSTO MOTTA MOREIRA - null